fig8

Figure 8. miR423-5p suppresses the expression of ribosomal genes and IRM genes. (A) RT-qPCR analysis showing the expression levels of miR-423-5p in BMSCs, IFNγ-BMSCs, native sEVs, and IFNγ-sEVs (n = 3 samples per group); (B) Molecular network showed miR-423-5p related to ribosome-IRM core network and miR-423-5p predicted to target RPLP0, IFITM3, and SAMHD1; (C) RT-qPCR analysis showing the levels of miR-423-5p in control BV2 cells, BV2 cells stimulated with LPS + IFNγ, and BV2 cells added either NC or miR-423-5p after LPS + IFNγ-stimulation (n = 3 samples per group); (D) Representative confocal images show the morphology of IBA1-stained BV2 cells treated with miR-423-5p mimics or NC for 48 h after being stimulated with LPS + IFNγ for 24 h. Scale bar, 20 μm; (E) The quantization of elongation, that is, the length of the long axis divided by the length of the short axis (n = 3 samples per group); (F-K) RT-qPCR analysis showing relative mRNA levels of ribosomal genes in the NC group and miR-423-5p-treated group (n = 3 samples per group); (L-Q) RT-qPCR analysis showing relative mRNA levels of IFN-responsive microglial genes in the NC group and miR-423-5p-treated group (n = 3 samples per group). Using one-way ANOVA (A and C). Using one-way ANOVA (A and C) and unpaired t-tests (E-Q). Data are shown as mean ± SD. IRM: Interferon-responsive microglia; RT-qPCR: reverse-transcription quantitative polymerase chain reaction; BMSCs: bone marrow mesenchymal stem cells; IFNγ: interferon-gamma; sEVs: small extracellular vesicles; NC: negative control; LPS: lipopolysaccharide; NS: no significant difference. ^*P < 0.05; ^**P < 0.01; ^***P < 0.001; ^****P < 0.0001.